Highlights Alkermes plc

Equities

ALKS

IE00B56GVS15

Real-time Estimate Cboe BZX Other stock markets 11:08:40 09/05/2024 pm IST			5-day change	1st Jan Change
24.16 ^USD	+0.23%		+1.30%	-12.87%

02/05	UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating	MT
01/05	Alkermes's Q1 Earnings, Revenue Grow But Miss Street View	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alkermes's Q1 Earnings, Revenue Grow But Miss Street View	01/05	MT
Earnings Flash (ALKS) ALKERMES Reports Q1 Revenue $350.4M, vs. Street Est of $360.3M	01/05	MT
Earnings Flash (ALKS) ALKERMES Posts Q1 EPS $0.43, vs. Street Est of $0.58	01/05	MT
Alkermes plc Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05	CI
Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday	09/04	MT
Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study	09/04	MT
Alkermes plc Announces Positive Topline Results from Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients with Narcolepsy Type 2 and Idiopathic Hypersomnia	09/04	CI
Alkermes Shares Rise After Q4 Results, Guidance	15/02	MT
Alkermes Q4 Non-GAAP Earnings, Revenue Increase; 2024 Outlook Issued -- Shares Gain Pre-Bell	15/02	MT
Earnings Flash (ALKS) ALKERMES Posts Q4 Revenue $377.5M, vs. Street Est of $362.4M	15/02	MT
Alkermes plc announces an Equity Buyback for $400 million worth of its shares.	15/02	CI
Alkermes plc Reports Earnings Results for the Full Year Ended December 31, 2023	15/02	CI
Alkermes plc Provides Earnings Guidance for the Year 2024	15/02	CI
Alkermes plc authorizes a Buyback Plan.	15/02	CI
Alkermes plc Announces Topline Results from Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI	03/01	CI
Alkermes to Sell Ireland Facility to Novo Nordisk	14/12	MT
Spin off	16/11	FA
Alkermes Completes Oncology Business Separation; Mural Oncology to Begin Trading Thursday	15/11	MT
Alkermes plc Revises Earnings Guidance for the Fiscal Year 2023	15/11	CI
Alkermes plc completed the spin-off of Mural Oncology plc for approximately ?260 million.	15/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alkermes plc

Equities

ALKS

IE00B56GVS15

Highlights

Filters